Tiny dialysis study hopes magnesium tweak calms blood cells
NCT ID NCT07206524
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tests whether adjusting magnesium levels in dialysis fluid can reduce harmful blood cell activation during treatment. Fifteen adults with kidney failure will try three different dialysis fluid recipes over six weeks. Researchers will measure blood cell counts and inflammation markers, but this is an early exploratory study, not a proven therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dialysate with varying magnesium concentrations (0.5, 0.75, 1.0 mmol/L) and acid type (acetic vs. citric)
What this could lead to
If successful, this could point toward a safer dialysis recipe that reduces inflammation and clotting risks for kidney patients.
What could go wrong
This is a very small pilot study (15 people) looking at lab markers, not patient outcomes. It may not lead to any practical changes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMODIALYSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitair Ziekenhuis Brussel
RECRUITINGBrussels, 1090, Belgium
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••